GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...

Annual Congress, CureGene Pharmaceuticals ("CureGene") announced late-breaking preclinical results for its investigational liver-targeted thyroid hormone receptor beta (THR-β) prodrug, CG-0416.

You might not think much about what makes a liver healthy or unhealthy. And when your liver starts to become unhealthy, you ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Aroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...